Jacobs Levy Equity Management
BIOL

Jacobs Levy Equity Management’s Biolase, Inc. BIOL Stock Holding History

Jacobs Levy Equity Management’s Portfolio BIOL Stock Details BIOL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-1
Closed -$23K – 1031
2017
Q1 		$23K Buy
+1
New +$18.1K ﹤0.01% 904
2016
Q3 		– Sell
-1
Closed -$15K – 1153
2016
Q2 		$15K Buy
+1
New +$15.8K ﹤0.01% 1138

Other funds holding BIOL

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
GIP
Granite Investment Partners El Segundo, California $1.63B AUM 38.09% 1-Year Est. Return
TMC
Trellus Management Company Delray Beach, Florida $72.8M AUM 4.5% 1-Year Est. Return
TA
Teton Advisors Rye, New York $142M AUM 42.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jacobs Levy Equity Management's BIOL Position: Q2 2017 in Review

Jacobs Levy Equity Management sold out of Biolase, Inc. (BIOL) in Q2 2017, closing a stake of 1 share — an estimated $23K sold.

Jacobs Levy Equity Management first reported a position in BIOL in Q2 2016 and held it in 2 quarters. The position peaked at $23K in Q1 2017. 32 funds tracked by Wall St. Rank hold BIOL as of Q2 2017.

  • Jacobs Levy Equity Management reported no remaining Biolase, Inc. position as of Q2 2017 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 1 Biolase, Inc. share in Q2 2017, an estimated $23K.
  • Jacobs Levy Equity Management first reported a position in Biolase, Inc. in Q2 2016 and held it in 2 quarters.
  • Jacobs Levy Equity Management's Biolase, Inc. position peaked at $23K in Q1 2017.
  • 32 funds tracked by Wall St. Rank held Biolase, Inc. as of Q2 2017.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2017, filed 14 Aug 2017.